论文部分内容阅读
目的:观察蒙脱石散联合双歧杆菌四联活菌片治疗腹泻型肠易激综合征的临床疗效.方法:将87例腹泻型肠易激综合征患者随机分为A组(治疗组)与B组(对照组),A组(治疗组)47例,B组(对照组)40例;B组(对照组)口服蒙脱石散治疗;A组(治疗组)在B组(对照组)的基础上加服用双歧杆菌四联活菌片;两组疗程均为4周.结果:A组(治疗组)总有效率91.5％,B组(对照组)总有效率72.5％,两组比较差异有统计学意义(P＜0.05).结论:蒙脱石散联合双歧杆菌四联活菌片治疗腹泻型肠易激综合征能迅速改变临床症状、疗效显著,值得临床应用.","Objective To observe the clinical effect of Montmorillonite powder Bifidobacterium Tetravaccine tablets in treatment of diarrhea type irritable bowel syndrome. Methods 87 cases of diarrhea predominant irritable bowel syndrome were randomly divided into group A (treatment group) and group B (control group), A group (treatment group) 47 cases, group B (control group) 40 cases; group B (control group) Montmorillonite powder oral treatment; A group (treatment group) in group B (control group) based on the use of Bifidobacterium Tetravaccine tablets; two groups were treated for 4 weeks. Results The total effective rate of group A (treatment group) was 91.5％, and the total effective rate in group B (control group) was 72.5％, and the difference between the two groups was statistically significant (P＜0.05). Conclusion Montmorillonite powder Bifidobacterium Tetravaccine tablets in treatment of diarrhea type irritable bowel syndrome can quickly change the clinical symptoms, curative effect, worthy of clinical application.